Heidi Capozzi previously served as chief people officer for McDonald’s.
CVS Health announced that Heidi Capozzi will serve as its new chief people officer.1 Prior to joining CVS Health, Capozzi was the chief people officer at McDonald’s and before that she worked at Boeing.
In a press release, Capozzi said, “I am excited to join CVS Health and be part of a team whose strategy is bold and necessary: redefining how health care is delivered in this country. I admire CVS Health for its leadership in imagining and delivering a personalized health care experience, and I am proud to join a company that is truly colleague and customer focused with a mission dedicated to improving health for everyone."
In the same press release, CVS Health president and CEO Karen S. Lynch said, “Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and advancing a winning culture. From nimble startups to established brands, Heidi has consistently applied her expertise to championing talent and we look forward to her being a part of our leadership team."
CVS Health also recently announced that it had provided $525,000 in Health Zones funding to Central California Food Bank’s (CCFB) City Center Initiative.2
In a press release, CVS Health senior vice president of corporate social responsibility and chief sustainability officer Sheryl Burke said, “When people have access to supportive services, it puts them in a better position to take care of their health and well-being. Our Health Zones organizations in Fresno share our vision of improving health outcomes locally. We believe that by working together and integrating our other community-based efforts through programs like Project Health, we will make a meaningful impact and improve community health here in Fresno."
Central California Food Bank co-CEO Kym Dildine added, “Through this collaborative, the CVS Health Foundation is helping the incredible partners at City Center leverage food and nutrition to connect neighbors to a wide array of community supports that will improve overall health and well-being.”
Also in August, CVS Health announced a new environmental health initiative for people impacted by extreme weather events, such as deadly heat waves or powerful storms, both of which are becoming more common occurrences in the United States.3
In a press release, practicing physician and chief clinical innovation officer at CVS Caremark Dr. Dan Knecht said, “Extreme heat kills more Americans each year than all other weather events combined. In addition to fatalities driven by heat strokes, extreme heat can worsen chronic conditions such as cardiovascular disease, asthma and chronic obstructive pulmonary disease. Most heat-related deaths are preventable with outreach and intervention. We are proud to introduce a new capability that advances our efforts to find innovative ways to deliver personalized health care to consumers."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.